Warner Chilcott and Leo Pharma have announced the FDA’s approval of their New Drug Application (NDA) for a topi cal ointment (Taclonex) to treat psoriasis vulgaris in adults. The product is a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064%. Taclonex is sold outside the U.S. as Dovobet and Daivobet.
canadian pharmacy viagra
Warner Chilcott is Leo Pharma’s exclusive licensee of Taclonex in the U.S. Taclonex is expected to be launched in the first half of 2006.